• E-mail :[email]
  • Phone : +33 1 42 16 57 07
  • Location : Paris, France
Last update 2011-09-01 11:11:27.778

Valérie Allamand PhD Human Genetics

Course and current status


 1995 : Ph.D. in Human Genetics, University Paris VII, France

1994 : «Advanced Linkage Analysis Course» organized by Pr Jurg Ott, Zurich (Switzerland)

1991 : D.E.A. (equivalent to Master) in Fundamental Bases of Oncogenesis, University Paris VII, France

1990 : Maîtrise (equivalent to Bachelor of Science) in Biology and Genetics, University Paris VII, France

 Research and Professional Experience                                                                                                             

2009-present  : Group leader at UMR S974-Institut de Myologie, Paris (France).                         Physiopathology and therapeutic approaches for ColVI-related myopathies

2006-2009  : Co-supervision of Perrine Castets’ PhD work “Roles of Selenoprotein N during development and muscle regeneration”.

2003 : Agreement for animal experimentation

2002-2008 : Senior Researcher (CR1 Inserm) at Inserm U582 (ex U523) in the group of Dr. Pascale  Guicheney, Institut de Myologie, Paris (France).    Physiopathology and therapeutic approaches for congenital muscular dystrophy

2001-2002 : Post-doctoral fellow in the group of Pascale Guicheney at Inserm U523, Institut de Myologie, Paris (France). Development of therapeutic approaches for congenital muscular dystrophy with laminin alpha2 chain deficiency

1996-2000 : Post-doctoral fellow in the laboratory of Kevin P. Campbell, HHMI, University of Iowa College of Medicine, Iowa City (USA). Gene therapy for Autosomal Recessive Limb-Girdle Muscular Dystrophy

1992-1995 : Ph.D. student in CNRS URA 1922-Généthon, Evry (France). Supervisor: Jacques S. Beckmann. Refined genetic mapping of the LGMD2A locus involved in a recessive form of limb-girdle muscular dystrophy

1991 : Graduate research in the Human and Molecular Laboratory of the Genetics Department, Trinity College, Dublin (Ireland). Supervisor: Peter Humphries.

Scientific summary

Mutations in the genes encoding collagen type VI (ColVI), a heterotrimeric molecule linking the basement membrane and interstitial matrix, are responsible for a group of neuromuscular disorders, clinically and genetically heterogeneous (Lampe and Bushby, 2008 ; Allamand et al., in press). ColVI-related myopathies have long been under-recognized and under-estimated; indeed, Ullrich congenital muscular dystrophy (UCMD), which represents the most severe end of the clinical spectrum, is most likely the most common form of “merosin-positive” CMD (i.e. without involvement of the alpha2 chain of laminin-211).
The projects developed in my group focus on: 1) defining the genetic and molecular bases of ColVI-myopathies; 2) understand the pathological mechanisms at play 3) develop and test novel therapeutic approaches.
Image d’exemple